Dianthus Therapeutics (NASDAQ:DNTH) Price Target Raised to $51.00 at Raymond James

Dianthus Therapeutics (NASDAQ:DNTH) had its target price boosted by Raymond James from $34.00 to $51.00 in a research note issued to investors on Thursday morning, Benzinga reports. Raymond James currently has an outperform rating on the stock.

DNTH has been the topic of several other reports. Wedbush boosted their price objective on shares of Dianthus Therapeutics from $24.00 to $33.00 and gave the company an outperform rating in a research note on Friday, March 22nd. Stifel Nicolaus assumed coverage on shares of Dianthus Therapeutics in a report on Thursday, February 15th. They issued a buy rating and a $44.00 target price on the stock. Finally, Jefferies Financial Group increased their price target on shares of Dianthus Therapeutics from $22.00 to $39.00 and gave the stock a buy rating in a report on Friday, March 22nd. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of Buy and an average target price of $42.40.

Dianthus Therapeutics Price Performance

Shares of DNTH opened at $23.63 on Thursday. The firm has a fifty day moving average price of $25.83 and a 200 day moving average price of $17.16. Dianthus Therapeutics has a 1-year low of $6.58 and a 1-year high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Thursday, March 21st. The company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.11) by $0.40. The company had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.73 million. As a group, equities analysts expect that Dianthus Therapeutics will post -1.92 EPS for the current fiscal year.

Institutional Investors Weigh In On Dianthus Therapeutics

Institutional investors have recently made changes to their positions in the stock. Atlas Venture Life Science Advisors LLC purchased a new position in shares of Dianthus Therapeutics in the 3rd quarter valued at about $3,240,000. FMR LLC purchased a new position in Dianthus Therapeutics in the third quarter valued at about $28,961,000. Citigroup Inc. purchased a new position in Dianthus Therapeutics in the third quarter valued at about $53,000. Acadian Asset Management LLC acquired a new stake in shares of Dianthus Therapeutics during the 3rd quarter valued at approximately $303,000. Finally, Avidity Partners Management LP purchased a new stake in shares of Dianthus Therapeutics during the 3rd quarter worth approximately $16,644,000. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.